Stock News

A US$15M partner payment arrived after quarter-end as research spending rose ahead of the Nov. 28 D-PLEX100 review goal.

TNR holders would receive Altius shares and a stake in an Alaska gold spinout, subject to shareholder, court and exchange approvals.

The Chilean project's infill program will add 3,300 metres to support an updated resource and a pre-feasibility study planned for 2027.

The 17-person sales team precedes planned January 2027 deliveries, with margins above 50 per cent forecast by the company.

The Nevada project retains late-2027 mechanical completion and a 2028 production ramp-up, with capital needs expected to remain funded.

Guardian expects to retain a significant stake in the new company and is not announcing a share distribution to existing holders.

Southern Cross Diagnostics can supply the DPYD assay for clinical use, but Novacyt has not dated its Australian commercial rollout.

Contracted GPU-cloud run rate includes undeployed capacity, while HIVE's year-end expansion target remains conditional on financing.

Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

Weekly brelovitug achieved a 59 per cent combined response, and Mirum plans an FDA filing in the first half of 2027.

True widths remain unknown as the first Skiråsen infill hole tests resource confidence at the wholly owned Swedish gold project.

Nine-month orders rose 611 per cent, but the third-quarter adjusted EBITDA loss widened to US$37.7 million.

Eight participants completed the placebo-controlled cohort; extension data are expected in January 2027 while a partial FDA hold remains.

DISA would own about 8.88 per cent after conversion, while a separate share transfer would take IsoEnergy's holding to 22.1 per cent.

The first US$200 million draw awaits customer acceptance and other conditions, with borrowing at a minimum 8 per cent before fees.

The initial refinery is designed for up to 600 tonnes of antimony a year, while larger production scenarios require more refining equipment.

The 86 per cent brain-response rate came from seven evaluable patients; lower-dose safety data are required before Phase 3.

All 53.40 bitcoin were pledged at Sept. 30, with US$5.05M of convertible debt due between January and April 2027.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

A switch to sodium peroxide fusion lifted results from 110 retested samples, with the peak grade coming from a 0.33-metre core interval.

Production is expected in 2029, subject to final government approvals, with flexibility to build hybrids, gasoline vehicles and EVs.

A US$65 million investment commitment remains subject to lease progress, while another 155,040 shares have been repurchased.

Eligible holders would receive about 40% of Anchor Metals, while a warrant pool could leave Benton without an equity stake.

The conceptual larger-pit option contains 4.4 million ounces, while a potential resource update is targeted for year-end.

Nine-month product revenue rose 92 per cent, while cash, equivalents and marketable securities stood at US$334.3 million at Sept. 30.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.

U.S. Briumvi sales grew approximately 52 per cent in the third quarter as TG increased its domestic sales forecast and kept spending guidance unchanged.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.

Three holes extend the East Zone 100 metres northwest, with eight more planned before the end of November and 16 awaiting assays.

The proposed share purchase has a price floor linked to an earlier US$2.5 billion valuation, with Japanese distribution agreements also planned.

The 370-patient randomized trial supports a planned year-end FDA filing, but response rates and detailed safety data remain undisclosed.

BLM's completeness finding leaves pipeline baseline studies and the level of environmental review to be settled before mine-plan approval.

A resource update and feasibility study are due by March 2027, following drilling above and outside the current resource.

Historical mine-dump material also returned 0.47 per cent antimony as the Utah explorer ranks targets for drilling in early 2027.

Lorundrostat's extension study showed a 17.8 mmHg reduction from baseline as an FDA decision approaches on Dec. 22.

European and Asian buying offset North American withdrawals, but lower gold prices cut global fund assets by 6 per cent.

The delayed-treatment arm recorded no responses, while Vir plans an FDA submission in mid-2027 after two further pivotal readouts.

New Phase 1/2 data cover durability across three autoimmune diseases and safety in 71 patients treated after preconditioning.

At week 16, 58 per cent achieved the main joint response versus 41 per cent on placebo; the oral drug is not approved for psoriatic arthritis.

Nine-month CyPath Lung revenue rose 79 per cent, while quarterly company revenue fell and Sept. 30 cash stood at US$2.6 million.